CN114533752A - Application of naringin in preparing medicament for treating chronic obstructive pulmonary disease - Google Patents
Application of naringin in preparing medicament for treating chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CN114533752A CN114533752A CN202210331739.5A CN202210331739A CN114533752A CN 114533752 A CN114533752 A CN 114533752A CN 202210331739 A CN202210331739 A CN 202210331739A CN 114533752 A CN114533752 A CN 114533752A
- Authority
- CN
- China
- Prior art keywords
- naringin
- chronic obstructive
- obstructive pulmonary
- application
- pulmonary disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 title claims abstract description 40
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 title claims abstract description 40
- 229940052490 naringin Drugs 0.000 title claims abstract description 40
- 229930019673 naringin Natural products 0.000 title claims abstract description 40
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 210000004072 lung Anatomy 0.000 claims abstract description 29
- 230000008719 thickening Effects 0.000 claims abstract description 6
- 230000009467 reduction Effects 0.000 claims abstract description 5
- 210000003437 trachea Anatomy 0.000 claims description 4
- 239000013618 particulate matter Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 abstract description 5
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000004199 lung function Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 5
- 229960002586 roflumilast Drugs 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000009798 acute exacerbation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004704 glottis Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a new application of naringin in preparing a medicine for treating chronic obstructive pulmonary disease. In particular to application of naringin in preparing medicaments for treating chronic obstructive pulmonary diseases induced by diesel PM2.5 particles, which comprises preparing medicaments for treating reduction of lung tissue elastic resistance, increase of lung tissue airway resistance or lung airway wall or alveolar cavity thickening induced by diesel PM2.5 particles. Tests prove that the naringin can be used as a pharmaceutical active ingredient and matched with a pharmaceutically acceptable carrier, provides basis for preventing and treating chronic obstructive pulmonary disease and improves the life quality of patients.
Description
Technical Field
The invention relates to the application of naringin in preparing medicine, in particular to the application of naringin in preparing medicine for treating chronic obstructive pulmonary disease.
Background
Naringin is an effective monomer extracted from exocarpium Citri Grandis (Lingnan) of Lingnan, is widely present in Citrus plants of Rutaceae, and has significant effects in relieving cough, eliminating phlegm, relieving inflammation, and resisting oxidation. Naringin has the following structure:
chronic Obstructive Pulmonary Disease (COPD) is a pulmonary disease characterized by airflow limitation which is not completely reversible and progresses in a progressive manner, the occurrence of which is associated with an abnormal inflammatory response of the lungs to harmful gases or harmful particles. With repeated attack and acute exacerbation, the lung function gradually declines, and shortness of breath is felt even during daily activities and even rest. COPD is of high prevalence, more common in the elderly, mainly caused by smoking, and is also associated with environmental pollutant concentrations. Approximately 300 million people die worldwide each year from COPD. With the increasing population of cigarette smokers in developing countries and the aging population in high income countries, the prevalence of COPD will continue to increase, estimated at 2030 that 450 million people will die from COPD-related diseases. While there are a number of pharmacological and non-pharmacological interventions currently available to prevent the onset of acute exacerbations of COPD, these approaches still have limited reduction in the frequency of episodes of acute exacerbations in patients. Therefore, it is important to develop a novel drug capable of effectively treating COPD.
Disclosure of Invention
The invention aims to disclose a new application of naringin in preparing a medicament for treating chronic obstructive pulmonary disease.
In particular to application of naringin in preparing medicaments for treating chronic obstructive pulmonary diseases induced by diesel PM2.5 particles, which comprises preparing medicaments for treating reduction of lung tissue elastic resistance, increase of lung tissue airway resistance or lung airway wall or alveolar cavity thickening induced by diesel PM2.5 particles.
The naringin can be matched with a pharmaceutically acceptable carrier and prepared into various common preparations according to a conventional production method. It is safe for oral administration and non-oral administration, and can be made into any conventional forms, such as granule, tablet, capsule, pill, oral liquid, spray or aerosol, suppository, injection, ointment, inhalant, etc.
The medicine for treating chronic obstructive pulmonary disease can be prepared into different formulations by a conventional method by selecting conventional auxiliary materials suitable for corresponding formulations or adding no auxiliary materials. The adjuvant can be solid, semisolid or liquid, and can be used as vehicle, excipient or medium of naringin.
According to the invention, Diesel Particulate Matters (DPM) serving as PM2.5 simulative agents are instilled to induce mice to generate COPD, and the treatment effect of naringin on COPD is researched on the basis. The experimental results show that: 1. the naringin of 30, 60 and 120mg/kg administered by intragastric administration has protective effect on lung function of COPD mice induced by DPM; 2. naringin has certain relieving effect on the pathological change of lung tissues of COPD mice; 3. naringin has inhibitory effect on DPM-induced inflammatory cell infiltration and inflammatory factor expression in COPD mice. The naringin can be used as a medicine active component and matched with a pharmaceutically acceptable carrier to prepare a medicine for treating chronic obstructive pulmonary disease, provides basis for preventing and treating COPD and improves the life quality of patients.
Detailed Description
The invention is further illustrated by the following examples. The examples of the present invention are intended to illustrate the present invention, not to limit the present invention. Simple modifications of the invention in accordance with its spirit fall within the scope of the claimed invention.
Example 1 Effect of Naringin on Lung function in mice model for COPD
Male ICR mice (SPF grade) weighing around 20g of 48 mice were randomly divided into six groups of 8 mice each. Normal control group, model group, naringin low and medium dosage group (30, 60, 120mg/kg) and positive control group. After the mice were adapted to be raised for 1 week, the mice were molded, injected with 10% chloral hydrate intraperitoneally, anesthetized, and placed on an inclined stand so as to be supine at an angle of 45 °. The mouth of the mouse was opened using a spatula, the glottis was found, the trachea was inserted through the glottis to the lungs using a special microinjection syringe, and DPM (0.5 mg/mouse, 50 μ L/mouse) was instilled. Keeping for 1-2min to uniformly diffuse DPM. The administration is performed by intragastric administration 1h before each instillation (the intragastric administration volume is 0.2mL), the administration doses of naringin are respectively 30, 60 and 120mg/kg (calculated by the prepared dry powder), the dose of the roflumilast in a positive control group is 5mg/kg, and the intragastric administration of the normal control group and a molding group is performed by using physiological saline with the same volume. After instillation and molding, the injection is continuously administered by gavage for 40 days in groups, once a day, and the mice are treated for test after administration for 1 hour on the 40 th day of the test.
And (3) lung function measurement: the mouse static compliance (Cchord), dynamic lung compliance (Cdyn), airway Resistance (RI), peak expiratory flow rate (PEF) were determined using a Buxco small animal lung function analysis system.
The experimental results are as follows: compared with a normal control group, the model group mice Ccpord and RI are increased, and Cdyn and PEF are reduced (p is less than 0.05 or p is less than 0.01). Naringin can reduce Cward and RI in a dose-dependent manner with significant differences (p < 0.05 or p < 0.01) compared with the model group. The naringin of 120mg/kg can increase mouse Cdyn and PEF, and has obvious difference compared with a model group (p is less than 0.05). The naringin is prompted to relieve the reduction of the elastic resistance of the lung tissue of the mouse caused by DPM, inhibit the collapse of the elastic fiber, reduce the airway resistance and improve the function of the small airway. The positive control drug roflumilast can also reduce Ccpord and RI, has a significant difference (p is less than 0.05) compared with a model group, and has no significant regulation and control on Cdyn and PEF. The results are shown in Table 1.
TABLE 1 Effect of Naringin on Lung function in COPD model mice
Note: compared with the normal group, # p < 0.05 or # p < 0.01; p < 0.05 or p < 0.01 compared to model groups.
Example 2 Effect of Naringin on pathological changes in the Lung of mice model COPD
The experimental groups, the molding method and the administration method were the same as in example 1.
Pathological observation of lung tissues of mice: and (4) preparing a section, staining by hematoxylin-eosin, and observing pathological changes of lung tissues of the mouse.
The experimental results are as follows: the normal group of mice has regular lung tissue structure, uniform alveoli distribution, complete alveolar wall without obvious collapse, complete tracheal wall without thickening and no obvious inflammatory cell aggregation and bleeding sites in tissues. Compared with the normal group of mice, the lung structure of the model group of mice is obviously changed, and the lung structure of the model group of mice comprises: the change of the tissue structure reduces the contact area of the lung gas exchange and increases the difficulty of the gas exchange, thereby reducing the lung function and influencing the normal respiratory physiological process. Naringin can attenuate DPM-induced lung tissue structural abnormalities to some extent, including: the regulation and control effects of recovering tracheal wall and alveolar cavity structures and inhibiting inflammatory cell aggregation and tissue bleeding have obvious dose-effect relationship, and the high dose has more obvious recovery effect. The positive control drug roflumilast can also inhibit lung tissue damage induced by DPM to a certain extent.
Example 3 Effect of Naringin on the number of blood leukocytes in mice model for COPD
The experimental groups, the molding method and the administration method were the same as in example 1.
Mouse orbital bleeds and leukocyte division counts: cutting two-side beard of each group of mice, using an elbow forceps to pull out one side of eyeball, collecting the flowing blood in a blood collection tube containing heparin sodium, using a full-automatic blood cell analyzer to perform blood leukocyte classification and counting, and respectively detecting the total number of leukocytes and the number of lymphocytes.
The experimental results are as follows: the total number of leukocytes and the number of lymphocytes were increased in the model group mice as compared with the normal group (p < 0.05). Compared with the model group, the total leukocyte and lymphocyte of the naringin administration group are obviously reduced (p is less than 0.05 or p is less than 0.01). Naringin mainly controls lymphocyte to increase DPM induced leukocyte. The roflumilast has obvious effect on inflammatory cells in blood of COPD mice, and the total number of leucocytes and the number of lymphocytes are obviously reduced (p is less than 0.05) compared with a model group. The results are shown in Table 2.
TABLE 2 Effect of Naringin on blood leukocyte count in COPD model mice
Note that # p is less than 0.05 compared with the normal group; p < 0.05 or p < 0.01 compared to model groups.
Example 4 Effect of Naringin on Lung tissue inflammation in COPD model mice
The experimental groups, the molding method and the administration method were the same as in example 1.
Mouse lung tissue immunohistochemistry: after cervical dislocation, the chest was opened to isolate lung tissue, which was fixed in 4% paraformaldehyde solution. After the tissues are embedded in paraffin and sliced, the tissues are baked for 2 hours at 60 ℃. The tissue slices are washed by water after dewaxing treatment, antigen retrieval is carried out, and then sealing treatment is carried out. Primary antibodies (IL-8, TNF-. alpha.and NF-. kappa.B) were incubated separately at 4 ℃ overnight. After washing with PBS, a secondary poly-HRP-labeled anti-mouse IgG antibody was added and incubated at room temperature for 1 h. And after being washed by PBS, the color is developed, the running water is turned to blue, and the water is dehydrated. The sections were finally mounted and observed under a microscope.
The experimental results are as follows: the lung tissues of normal mice have no obvious IL-8, TNF-alpha and NF-kappa B expression, and the lung tissues have regular structure, uniform alveolar distribution, complete alveolar walls without obvious collapse, complete tracheal walls without thickening and no obvious inflammatory cell aggregation. Compared with the normal group of mice, the lung IL-8, TNF-alpha and NF-kappa B expressions of the model group of mice are all obviously increased and are obviously expressed near the deposition of trachea ring DPM. Naringin can significantly reduce the expression of IL-8, TNF-alpha and NF-kappa B in tissues, and has anti-inflammatory effect. The effect of high-dose naringin on inhibiting the increase of the expression of the inflammatory factors induced by the DPM is more obvious. In addition, naringin can restore tissue structure, and inhibit thickening of trachea wall and alveolar cavity caused by DPM. The positive control drug roflumilast can also obviously inhibit the DPM-induced increase of IL-8, TNF-alpha and NF-kappa B expression and tissue structure lesion, and has anti-inflammatory effect.
Claims (5)
1. Application of naringin in preparing medicine for treating chronic obstructive pulmonary disease is provided.
2. Application of naringin in preparing medicine for treating chronic obstructive pulmonary disease induced by diesel PM2.5 particulate matter is provided.
3. Application of naringin in preparing medicine for treating lung tissue elastic resistance reduction induced by diesel PM2.5 particulate matter is provided.
4. Application of naringin in preparing medicine for treating lung tissue airway resistance increase induced by diesel PM2.5 particulate matter is provided.
5. Application of naringin in preparing medicine for treating lung trachea wall or alveolar cavity thickening induced by diesel PM2.5 particulate matter is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210331739.5A CN114533752A (en) | 2022-04-01 | 2022-04-01 | Application of naringin in preparing medicament for treating chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210331739.5A CN114533752A (en) | 2022-04-01 | 2022-04-01 | Application of naringin in preparing medicament for treating chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114533752A true CN114533752A (en) | 2022-05-27 |
Family
ID=81666102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210331739.5A Pending CN114533752A (en) | 2022-04-01 | 2022-04-01 | Application of naringin in preparing medicament for treating chronic obstructive pulmonary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114533752A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463142A (en) * | 2022-10-14 | 2022-12-13 | 广东省科学院动物研究所 | Application of naringin dihydrochalcone in preparation of medicine for treating pulmonary fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1468602A (en) * | 2003-06-18 | 2004-01-21 | 中山大学 | Application of naringin in preparing medicine for supporting treatment of SARS |
| CN106728205A (en) * | 2016-12-29 | 2017-05-31 | 中山大学 | Application of the Exocarpium Citri Grandis extract in preventing and treating PM2.5 particle inducing chronic obstructive disease of lung acute attack medicines are prepared |
-
2022
- 2022-04-01 CN CN202210331739.5A patent/CN114533752A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1468602A (en) * | 2003-06-18 | 2004-01-21 | 中山大学 | Application of naringin in preparing medicine for supporting treatment of SARS |
| CN106728205A (en) * | 2016-12-29 | 2017-05-31 | 中山大学 | Application of the Exocarpium Citri Grandis extract in preventing and treating PM2.5 particle inducing chronic obstructive disease of lung acute attack medicines are prepared |
Non-Patent Citations (4)
| Title |
|---|
| 岳勤霏等: "基于网络药理学的金水六君煎治疗慢性阻塞性肺疾病作用机制研究" * |
| 李沛波等: "柚皮苷及其苷元柚皮素的呼吸系统药理作用研究概述" * |
| 李泮霖等: "采用iTRAQ技术研究柚皮苷对烟熏所致小鼠急性肺部炎症相关蛋白表达的影响" * |
| 苏薇薇等: "柚皮苷对慢性阻塞性肺疾病气道炎症消退的调控作用及机制研究" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463142A (en) * | 2022-10-14 | 2022-12-13 | 广东省科学院动物研究所 | Application of naringin dihydrochalcone in preparation of medicine for treating pulmonary fibrosis |
| CN115463142B (en) * | 2022-10-14 | 2023-06-30 | 广东省科学院动物研究所 | Application of naringin dihydrochalcone in preparation of medicines for treating pulmonary fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117137998B (en) | Pharmaceutical composition for treating yin deficiency damp-heat type viral infection and pulmonary nodule, preparation and application thereof | |
| CN111773211B (en) | Application of haemagglutinin in preparation of anti-rheumatoid arthritis drugs | |
| CN113521101A (en) | Application of exosome derived from stem cells in preparation of medicine for treating chronic obstructive pulmonary disease | |
| CN114533752A (en) | Application of naringin in preparing medicament for treating chronic obstructive pulmonary disease | |
| US20200297793A1 (en) | Traditional chinese medicine composition for treating interstitial pulmonary fibrosis and method for making same | |
| Meuret et al. | Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone | |
| CN102397458B (en) | Medicinal composition for treating senile pneumonia and preparation method thereof | |
| CN114796183A (en) | Application of leonurine in preparation of medicine for preventing or treating respiratory system diseases | |
| US11179409B2 (en) | Cucurbitane tetracyclic triterpenoid compounds for application in treating pulmonary fibrosis | |
| CN112076247A (en) | Application of perilla leaf extract in preparation of medicine for treating chronic obstructive pulmonary disease | |
| CN109096360B (en) | Small molecule compound for treating rheumatoid arthritis and application thereof | |
| CN111467467A (en) | Application of substance obtained from volatile oil of Zingiberis rhizoma in treating acute pulmonary inflammation | |
| WO2020187018A1 (en) | Traditional chinese medicine composition for loosening bowels to relieve constipation, preparation method therefor and use thereof | |
| CN116785393B (en) | Traditional Chinese medicine composition for treating progressive pulmonary fibrosis and application thereof | |
| CN115715784B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis, application and pharmaceutical preparation thereof | |
| CN113134000B (en) | Pharmaceutical composition containing relaxing smooth muscle | |
| CN115845021B (en) | A Chinese medicinal composition for preventing and treating pulmonary fibrosis, and its preparation method | |
| CN113827636B (en) | Lung-clearing mixture containing Tibetan four ingredients and application thereof in preparation of medicines for treating respiratory system diseases | |
| CN111096997B (en) | Application of ficus microcarpa extract in preventing or treating interstitial lung diseases | |
| CN116870122B (en) | Traditional Chinese medicine composition for treating pediatric adenoid hypertrophy and application thereof | |
| CN110946947B (en) | Application of Miao medicine fruit upper leaves in preparation of medicine for preventing and treating chronic obstructive pulmonary disease | |
| CN110051778B (en) | Sore throat relieving tea for treating chronic pharyngitis and preparation method thereof | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN116421664A (en) | Application of coptis detoxification soup in preparation of medicines for treating respiratory tract induced lung injury | |
| EP4364748A1 (en) | Use of traditional chinese medicine composition in preparation of drug for treating cough variant asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220527 |